UNITED STATES SECURITIES AND EXCHANGE COMMISSION Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification No.) | | 1920 McKinney Avenue, 7th Floor | | | Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Mar ...

| --- | --- | --- | |-------------------------------------------------------------------------|-------|-------| | Lantern Pharma Company Overview April 6, 2021 | | | | Leveraging A.I., Machine Learning & Genomics to Rescue, Reposition and | | | | Develop Targeted Cancer Therapies | | | FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2020 Earnings Conference Call March 10, 2021 4:00 PM ET Company Participants Marek Ciszewski - Director, IR Panna Sharma - President and CEO David Margrave - CFO Conference Call Participants Kyle Bauser - Colliers Securities Daniel Carlson - TW Research Group John Vandermosten - Zacks Small Cap Operator Good afternoon and welcome to Lantern Pharma’s Fourth Quarter 2020 Conference Call. As a reminder, this call is being recorded and all participants are in listen-only mod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2020 Results Conference Call October 29, 2020 4:00 PM ET Company Participants Marek Ciszewski - Director, IR Panna Sharma - President and CEO David Margrave - CFO Conference Call Participants Kyle Bauser - Colliers John Vandermosten - Zacks Small Cap Operator Good afternoon and welcome to Lantern Pharma’s Third Quarter 2020 Conference Call. As a reminder, this call is being recorded and all participants are in listen-only mode. We will open the call for questions-and-ans ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS ...

| --- | --- | --- | |------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and | | | | Develop Targeted Cancer Therapies | | | SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS • This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ...